Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | DNM2 | P50570 | 4/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10604098 | 0.93 | HCAR3 (0.59) | HCAR3KDM4EMAPTALDH1A1GAA | |
| Bromide SCHEMBL10609035 | 0.91 | HCAR3 (0.58) | HCAR3KDM4EMAPTALDH1A1GAA | |
| SCHEMBL10293613 | 0.85 | HCAR3 (0.57) | HCAR3KDM4EMAPTALDH1A1GAA | |
| SCHEMBL6645913 | 0.83 | MAPT (0.53) | HCAR3KDM4EMAPTALDH1A1GAA | |
| SCHEMBL11707466 | 0.81 | HCAR3 (0.57) | HCAR3KDM4EMAPTALDH1A1GAA | |
| SCHEMBL10737266 | 0.81 | HRH3 (0.47) | HCAR3KDM4EMAPTALDH1A1GAA | |
| SCHEMBL11563635 | 0.80 | RAB9A (0.58) | KDM4EALDH1A1HPGDRAB9AL3MBTL1 | |
| SCHEMBL7154180 | 0.79 | HCAR3 (0.59) | HCAR3MAPTALDH1A1HPGDCNR2 | |
| SCHEMBL7150739 | 0.79 | HCAR3 (0.59) | HCAR3KDM4EMAPTALDH1A1GAA | |
| SCHEMBL11257156 | 0.79 | HCAR3 (0.58) | HCAR3MAPTCNR2DNM2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-31 | — | — | US | disclosed |
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | disclosed |
| EP-3914592-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | University of Virginia Patent Foundation (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020154431-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | LYNCH KEVIN R (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | HCAR3 4414/4885KDM4E 4246/4885MAPT 22/4885 |
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | SPNS2, SLC20A2, S1PR2 | HCAR3 4183/4885KDM4E 1798/4885MAPT 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.